Search the webpage

A blue banner announces the acquisition of Ophthy-DS Ophthalmic CRO business by Experimentica

Scientific Excellence in Ocular Models ℠

Sponsors need more than models to successfully accelerate ophthalmic drug discovery efforts. They look for models and preclinical development plans backed by deep expertise and strong R&D. This gives drug candidates a clear pathway from proof of concept to IND-enabling studies.

From cell culture-based systems to complex in vivo models, Experimentica’s scientists apply their comprehensive set of skills to model ocular diseases.
Our customers can also rely on our global presence and industry-leading portfolio to deliver the highest quality science.
As a result, our teams efficiently assist sponsors worldwide in advancing the development of their ophthalmic drug candidates.

Former Ophthy-DS customer? Outstanding relationship with Jeff Jamison and Marianna Bacellar-Galdino? Good. They are on the team.

About Us

Contact Us to learn more


May 22, 2020 – Forest Park, IL – Experimentica Ltd., a leader in preclinical ophthalmic drug discovery services, announces the successful acquisition of the contract research division from Ophthy-DS, Inc., a Michigan-based preclinical contract research organization (CRO) specializing in non-regulated drug discovery services and medical device testing for ophthalmic indications.>> Full Press Release (PDF)